Autolus Therapeutics (AUTL) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
10 Nov, 2026Executive summary
Q3 AUCATZYL net product revenue was $41.238M, up 95% YoY; 9M revenue reached $113.1M, up 122%.
FY2026 revenue is expected to meet or exceed $150M; Q3 gross margin reached 57%.
Financial highlights
Q3 net product revenue was $41.238M vs. $21.144M; cost of sales was $17.927M vs. $28.643M.
R&D expense was $30.900M vs. $27.892M; SG&A was $35.946M vs. $36.280M.
Operating loss narrowed to $43.535M from $71.621M; net loss narrowed to $55.1M from $79.1M.
Nine-month net loss was $165.8M; operating cash use fell to $108.9M from $216.2M YoY.
Q3 basic and diluted loss per share was $0.21 vs. $0.30 YoY.
Outlook and guidance
FY2026 AUCATZYL revenue is expected to meet or exceed $150M, the upper end of prior guidance.
Gross margin is expected to improve with higher volumes and cost efficiencies; the peak gross-margin target is 65–70%.
Current plans, anticipated AUCATZYL proceeds and $100M from the first and second Perceptive tranches are projected to fund operations into Q2 2028.
BOBCAT enrollment is expected to finish in Q1 2027; initial data presentation is planned for October 2027, with up to 24 patients and at least 12 with 12+ months of follow-up.
R&D expense is expected to increase substantially as additional trials begin; operating losses are expected to continue.
Latest events from Autolus Therapeutics
- AUCATZYL scales commercially as margin gains and new indications build the next growth drivers.AUTL
Jefferies Global Healthcare Conference - AUCATZYL growth and expanding obe-cel trials broaden the commercial opportunity.AUTL
Corporate presentation - IPO-funded cash supports expanding T-cell trials, but losses and clinical risks remain significant.AUTL
Q4 2018 - A £113.5m loss funded a growing T-cell pipeline, with COVID-19 clouding timelines.AUTL
Q4 2019 - Cash runway extended to May 2023 as clinical development drives continued losses.AUTL
Q4 2021 - Licensing growth and a £316.3m cash balance offset a wider loss, with funding needed beyond June 2024.AUTL
Q4 2022 - Obe-cel advanced toward a 2024 decision, backed by encouraging data and $600M in February proceeds.AUTL
Q4 2023 - Resale registration for 3.5M ADSs linked to a warrant, supporting T cell therapy expansion.AUTL
Registration filing - Q2 2026 revenue surged 119% year-over-year, with gross margin at 55% and guidance raised.AUTL
Q2 2026